Bioventus: A New Start [Seeking Alpha]
Bioventus Inc. - Class A (BVS)
Company Research
Source: Seeking Alpha
The company trades at compelling valuation multiples—below 2x sales, ~7x adjusted EBITDA, and ~11x adjusted earnings—supported by accelerating organic revenue growth. Recent refinancing is set to reduce annual interest costs by over $2 million, and net debt has declined to $280 million, lowering leverage to around 2.5x. With continued sales and margin growth, disciplined capital allocation could enable Bioventus shares to revisit the teens by 2026. Maskot/DigitalVision via Getty Images In the spring of 2022, I offered some thoughts after an active first year in the case of Bioventus ( BVS . After being hyperactive on the dealmaking front, there were many moving parts into 2022, and while investors were not convinced that value More on my IG service If you like to see more ideas, please subscribe to the premium service "Value in Corporate Events" here and try the free trial. In this service we cover major earnings events, M&A, IPOs and other significant corporate events wi
Show less
Read more
Impact Snapshot
Event Time:
BVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BVS alerts
High impacting Bioventus Inc. - Class A news events
Weekly update
A roundup of the hottest topics
BVS
News
- Bioventus to Present at the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Bioventus to Present at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
- Bioventus (NASDAQ:BVS) had its "sell (d+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Bioventus reiterates 2025 guidance with 6%–8% organic growth target as PNS and PRP launches gain traction [Seeking Alpha]Seeking Alpha
- Bioventus Reports Third Quarter Financial ResultsGlobeNewswire
BVS
Earnings
- 8/6/25 - Miss
BVS
Sec Filings
- 12/4/25 - Form 144
- 11/25/25 - Form 3
- 11/17/25 - Form 8-K
- BVS's page on the SEC website